drugset / Trial / NCT07577570

Calcium Replacement Therapy in Postoperative Hypoparathyroidism

NCT07577570

RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this clinical trial is to evaluate whether a lower-dose calcium replacement therapy is non-inferior to a higher-dose regimen in preventing symptomatic hypoparathyroidism in patients following thyroidectomy. The hypothesis is: • lower-dose calcium replacement therapy is non-inferior to higher-dose therapy in preventing symptomatic hypoparathyroidism during the first two postoperative weeks Researchers will compare patients receiving a lower-dose calcium replacement regimen with those receiving a higher-dose regimen to assess whether the lower dose is not associated with a higher incidence of symptomatic hypoparathyroidism. Patients who develop post-thyroidectomy hypoparathyroidism are divided into groups for calcium replacement therapy. If they are asymptomatic, they will be scheduled for a follow-up visit at two weeks after surgery. During the follow-up visit, calcium metabolism will be evaluated, and treatment adjusted if necessary.

Timeline

Start
2025-11-18
Primary completion
2027-10
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcium carbonate Other / unclassified 1250 mg

Indications